Keck School Faculty

Paul Stephen Aisen

Paul Stephen Aisen

Professor of Neurology
Director, Alzheimer's Therapeutic Research Institute
ATRI 9860 Mesa Rim Road Health Sciences Campus San Diego

Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease JAMA Neurol. 2020 Jun 22. . View in PubMed

Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals JAMA Neurol. 2020 Apr 06. . View in PubMed

Authors response to D Umbricht, letter to the editor referring Futility Analyses in Alzheimer's Disease (AD) Clinical Trials: A Risky BusinessThe Journal of Prevention of Alzheimer's Disease, 2020. J Prev Alzheimers Dis. 2020; 7(4):300. . View in PubMed

Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults Neurobiol Aging. 2019 10; 82:110-119. . View in PubMed

A randomized clinical trial to evaluate home-based assessment of people over 75 years old Alzheimers Dement. 2019 05; 15(5):615-624. . View in PubMed

Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention CNS Drugs. 2019 02; 33(2):99-106. . View in PubMed

Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force J Prev Alzheimers Dis. 2019; 6(3):157-163. . View in PubMed

Automated and manual hippocampal segmentation techniques: Comparison of results, reproducibility and clinical applicability Neuroimage Clin. 2019; 21:101574. . View in PubMed

Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018 J Prev Alzheimers Dis. 2019; 6(3):198-203. . View in PubMed

Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial JAMA Neurol. 2018 07 01; 75(7):834-841. . View in PubMed

Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative Alzheimers Dement (Amst). 2018; 10:657-668. . View in PubMed

Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer's Disease in EXPEDITION 3 J Prev Alzheimers Dis. 2018; 5(3):184-187. . View in PubMed

Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force J Prev Alzheimers Dis. 2018; 5(2):103-109. . View in PubMed

A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease Alzheimers Dement (N Y). 2018; 4:46-53. . View in PubMed

Author response: A phase 3 trial of IV immunoglobulin for Alzheimer disease Neurology. 2018 01 16; 90(3):145. . View in PubMed

A phase 3 trial of IV immunoglobulin for Alzheimer disease Neurology. 2017 May 02; 88(18):1768-1775. . View in PubMed

Association between tau deposition and antecedent amyloid-ß accumulation rates in normal and early symptomatic individuals Brain. 2017 May 01; 140(5):1499-1512. . View in PubMed

Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease BMC Med Genomics. 2017 05 24; 10(Suppl 1):29. . View in PubMed

Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons JAMA. 2017 06 13; 317(22):2305-2316. . View in PubMed

Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia Am J Geriatr Psychiatry. 2016 Feb; 24(2):126-35. . View in PubMed

Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults JAMA Neurol. 2016 06 01; 73(6):721-32. . View in PubMed

Accelerating rates of cognitive decline and imaging markers associated with ß-amyloid pathology Neurology. 2016 05 17; 86(20):1887-96. . View in PubMed

CAP--advancing the evaluation of preclinical Alzheimer disease treatments Nat Rev Neurol. 2016 Jan; 12(1):56-61. . View in PubMed

APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern Alzheimers Dement. 2015 Dec; 11(12):1417-1429. . View in PubMed

A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS) J Prev Alzheimers Dis. 2015 Dec 01; 2(4):227-241. . View in PubMed

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease Neurology. 2015 Oct 20; 85(16):1383-91. . View in PubMed

Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans Alzheimers Dement. 2015 Jul; 11(7):734-9. . View in PubMed

2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception Alzheimers Dement. 2015 Jun; 11(6):e1-120. . View in PubMed

Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease Ann Clin Transl Neurol. 2015 May; 2(5):534-47. . View in PubMed

Advances in Alzheimer's disease drug development BMC Med. 2015 Mar 25; 13:62. . View in PubMed

Brain structure and function as mediators of the effects of amyloid on memory Neurology. 2015 Mar 17; 84(11):1136-44. . View in PubMed

Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future Expert Rev Neurother. 2015 Jan; 15(1):83-105. . View in PubMed

Alzheimer's disease progression by geographical region in a clinical trial setting Alzheimers Res Ther. 2015; 7(1):43. . View in PubMed

2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease Alzheimers Dement. 2014 Oct; 10(5 Suppl):S430-52. . View in PubMed

Alzheimer's Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study J Am Geriatr Soc. 2014 May; 62(5):985-8. . View in PubMed

APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study Mol Psychiatry. 2014 Mar; 19(3):351-7. . View in PubMed

Association of plasma and cortical amyloid beta is modulated by APOE e4 status Alzheimers Dement. 2014 Jan; 10(1):e9-e18. . View in PubMed

A phase 3 trial of semagacestat for treatment of Alzheimer's disease N Engl J Med. 2013 Jul 25; 369(4):341-50. . View in PubMed

Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly Neuropsychology. 2013 Jul; 27(4):391-401. . View in PubMed

Apolipoprotein E epsilon4 does not modulate amyloid-ß-associated neurodegeneration in preclinical Alzheimer disease AJNR Am J Neuroradiol. 2013 Mar; 34(3):505-10. . View in PubMed

Antioxidants for Alzheimer disease-reply JAMA Neurol. 2013 Feb; 70(2):270-1. . View in PubMed

Amyloid deposition, hypometabolism, and longitudinal cognitive decline Ann Neurol. 2012 Oct; 72(4):578-86. . View in PubMed

Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures Arch Neurol. 2012 Jul; 69(7):836-41. . View in PubMed

Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials Arch Neurol. 2012 Jul; 69(7):901-5. . View in PubMed

Amyloid-ß--associated clinical decline occurs only in the presence of elevated P-tau Arch Neurol. 2012 Jun; 69(6):709-13. . View in PubMed

Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology J Nutr Health Aging. 2012 Apr; 16(4):339-45. . View in PubMed

Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3985-90. . View in PubMed

Biomarkers for Alzheimer's disease therapeutic trials Prog Neurobiol. 2011 Dec; 95(4):579-93. . View in PubMed

Amyloid-ß associated volume loss occurs only in the presence of phospho-tau Ann Neurol. 2011 Oct; 70(4):657-61. . View in PubMed

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease Neurology. 2011 Aug 09; 77(6):556-63. . View in PubMed

AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials Alzheimers Dement. 2011 Jul; 7(4):e109-17. . View in PubMed

A phase II trial of huperzine A in mild to moderate Alzheimer disease Neurology. 2011 Apr 19; 76(16):1389-94. . View in PubMed

Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease Alzheimer Dis Assoc Disord. 2011 Apr-Jun; 25(2):122-7. . View in PubMed

A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice PLoS One. 2011 Jan 17; 6(1):e16259. . View in PubMed

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease Alzheimers Res Ther. 2011 Jan 06; 3(1):1. . View in PubMed

A lead study on oxidative stress-mediated dehydroepiandrosterone formation in serum: the biochemical basis for a diagnosis of Alzheimer's disease J Alzheimers Dis. 2011; 24 Suppl 2:5-16. . View in PubMed

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease Brain. 2010 Nov; 133(11):3336-48. . View in PubMed

3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects Neurobiol Aging. 2010 Aug; 31(8):1284-303. . View in PubMed

Biological markers of amyloid beta-related mechanisms in Alzheimer's disease Exp Neurol. 2010 Jun; 223(2):334-46. . View in PubMed

3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI Hum Brain Mapp. 2010 May; 31(5):786-97. . View in PubMed

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization Neurology. 2010 Jan 19; 74(3):201-9. . View in PubMed

Alzheimer's disease therapeutic research: the path forward Alzheimers Res Ther. 2009 Jul 09; 1(1):2. . View in PubMed

Can lithium or valproate untie tangles in Alzheimer's disease? J Clin Psychiatry. 2009 Jun; 70(6):919-21.. View in PubMed

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects Ann Neurol. 2009 Apr; 65(4):403-13. . View in PubMed

A roadmap for the prevention of dementia II: Leon Thal Symposium 2008 Alzheimers Dement. 2009 Mar; 5(2):85-92. . View in PubMed

Agreement in cognitive and clinical assessments in Alzheimer's disease Dement Geriatr Cogn Disord. 2009; 27(4):344-52. . View in PubMed

Applications of neuroimaging to disease-modification trials in Alzheimer's disease Behav Neurol. 2009; 21(1):129-36. . View in PubMed

Amyloid-based therapeutics: findings translated into novel treatments CNS Spectr. 2008 Oct; 13(10 Suppl 16):36-8. . View in PubMed

A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium Alzheimers Dement. 2008 May; 4(3):156-63. . View in PubMed

Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo Neurosci Lett. 2008 Apr 25; 435(3):186-9. . View in PubMed

A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease J Pharmacol Exp Ther. 2008 Apr; 325(1):146-53. . View in PubMed

An update on huperzine A as a treatment for Alzheimer's disease Expert Opin Investig Drugs. 2008 Feb; 17(2):209-15. . View in PubMed

An aspirin a day for Alzheimer's disease? Lancet Neurol. 2008 Jan; 7(1):20-1.. View in PubMed

Alzhemed: a potential treatment for Alzheimer's disease Curr Alzheimer Res. 2007 Sep; 4(4):473-8. . View in PubMed

Antibody against C-terminal Abeta selectively elevates plasma Abeta Neuroreport. 2007 Feb 12; 18(3):293-6. . View in PubMed

A simple method to rule out dementia with temporal orientation Alzheimers Dement. 2007 Jan; 3(1):28-32. . View in PubMed

BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice J Neurochem. 2006 Dec; 99(6):1555-63. . View in PubMed

A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease Neurology. 2006 Nov 28; 67(10):1757-63. . View in PubMed

ADCS Prevention Instrument Project: overview and initial results Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S109-23. . View in PubMed

ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI) Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S170-8. . View in PubMed

Can rofecoxib delay a diagnosis of Alzheimer's disease in patients with mild cognitive impairment? Nat Clin Pract Neurol. 2005 Nov; 1(1):20-1.. View in PubMed

An Abeta sequestration approach using non-antibody Abeta binding agents Curr Alzheimer Res. 2005 Apr; 2(2):265-8. . View in PubMed

Benchmarking a test of temporal orientation with data from american and taiwanese persons with Alzheimer's disease and american normal elderly Neuroepidemiology. 2005; 24(1-2):110-6. . View in PubMed

Anti-inflammatory therapy in Alzheimer's disease: is hope still alive? J Neurol. 2003 Jul; 250(7):788-92.. View in PubMed

A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease Am J Geriatr Psychiatry. 2003 Mar-Apr; 11(2):246-9. . View in PubMed

Anti-inflammatory agents in Alzheimer's disease Curr Neurol Neurosci Rep. 2002 Sep; 2(5):405-9. . View in PubMed

Chemistry and biology of eukaryotic iron metabolism Int J Biochem Cell Biol. 2001 Oct; 33(10):940-59. . View in PubMed

Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique Neurosci Lett. 2001 Feb 09; 298(3):191-4. . View in PubMed

Anti-inflammatory therapy for Alzheimer's disease Neurobiol Aging. 2000 May-Jun; 21(3):447-8; discussion 451-3. . View in PubMed

A randomized controlled trial of prednisone in Alzheimer's diseaseAlzheimer's Disease Cooperative Study. Neurology. 2000 Feb 08; 54(3):588-93. . View in PubMed

Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial Acta Neurol Scand Suppl. 2000; 176:85-9. . View in PubMed

Association of elevated alpha 1-antichymotrypsin with cognitive impairment in a prospective study of the very old Am J Psychiatry. 1998 May; 155(5):698-700. . View in PubMed

A kinetically active site in the C-lobe of human transferrin Biochemistry. 1997 Sep 09; 36(36):11036-43. . View in PubMed

A pilot study of prednisone in Alzheimer's disease Dementia. 1996 Jul-Aug; 7(4):201-6. . View in PubMed

Antinuclear antibodies in multiple sclerosis Neurology. 1995 Dec; 45(12):2299-300;author reply 2300-1. . View in PubMed

A pilot study of clonidine plus physostigmine in Alzheimer's disease Dementia. 1994 Sep-Oct; 5(5):243-6. . View in PubMed

A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease Alzheimer Dis Assoc Disord. 1993; 7(2):98-104. . View in PubMed

Antisense suppression of transferrin receptor gene expression in a human hepatoma cell (HuH-7) line Am J Hematol. 1993 Jan; 42(1):74-80. . View in PubMed

Catalysis of the Haber-Weiss reaction by iron-diethylenetriaminepentaacetate J Inorg Biochem. 1992 Dec; 48(4):241-9. . View in PubMed

A new role for the transferrin receptor in the release of iron from transferrin Biochemistry. 1991 Jan 15; 30(2):324-8. . View in PubMed

Paul Aisen, M.D., has been appointed founding director of USC ATRI. Aisen has been a leading figure in Alzheimer’s disease research for more than two decades, having developed novel methodologies as well as designed and directed many large therapeutic trials. He received his B.A. in biochemistry and molecular biology from Harvard and his medical degree from Columbia. He completed his residency at Case Western Reserve University in Cleveland and Mount Sinai Medical Center in New York, and then fellowship training in rheumatology at New York University. After serving as chief medical resident at Mount Sinai, he began a solo practice in internal medicine and rheumatology in New York. Aisen joined the faculty of Mount Sinai in 1994 and was recruited to Georgetown University in 1999 as a professor of neurology and medicine. That year, he founded the Memory Disorders Program, a clinical and research program for Alzheimer’s disease and related disorders. He continued basic research studies on therapeutic targets and biomarkers and designed and directed multicenter therapeutic trials. He became vice chair of the Department of Neurology at Georgetown in 2004. From 2007 through 2015, he was professor in the Department of Neurosciences at the University of California, San Diego and director of the Alzheimer’s Disease Cooperative Study.
Powered by SC CTSI
Go to Top